RECURSION PHARMACEUTICALS, INC. (RXRX) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $70.95M | +56.8% |
| 2024 | $45.24M | +6.2% |
| 2023 | $42.59M | -11.8% |
| 2022 | $48.27M | — |
| 2021 | $0 | — |
| 2020 | $0 | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $70.95M | +56.8% |
| 2024 | $45.24M | +6.2% |
| 2023 | $42.59M | -11.8% |
| 2022 | $48.27M | — |
| 2021 | $0 | — |
| 2020 | $0 | — |